Biotechnology

With a cash runway into 2029, Avalyn Pharma is advancing a novel inhaled drug platform, hitting key clinical milestones to challenge an oral-dominated market.

With wheat prices soaring, a new biosolution from Novonesis allows pasta makers to de-risk supply chains by using common wheat, securing a global staple.

A new composition of matter patent extends protection for Alterity's lead drug to 2045, de-risking its path in MSA and opening a new front against Parkinson's.

With breakthrough dialysis data and a new heart-mending vessel, Humacyte is balancing radical innovation with commercial reality. Is this the future of medicine?

Early data for Sutro Biopharma's STRO-004 offers a glimmer of hope for advanced cancer patients. We look at the tech, the trials, and the financial tightrope.

RyboDyn's RyboCypher platform is uncovering a 'dark proteome' full of tumor-specific targets, promising a new era beyond today's crowded drug pipeline.

Amid a selective biotech market, Rakovina Therapeutics' oversubscribed placement highlights investor belief in its AI-powered strategy for next-gen cancer drugs.

A biotech's new funding offers a glimmer of hope for a novel cancer therapy, but a look at the books reveals a desperate race against time and capital.

Aardvark Therapeutics faces a pivotal moment as an FDA clinical hold halts its lead drug trial, leaving the Prader-Willi Syndrome community waiting.

BridgeBio Oncology is doubling down on a costly strategy, betting that combining its novel drugs is the key to defeating hard-to-treat RAS-driven cancers.

With pivotal data imminent for two cancer drugs and a fortified balance sheet, SELLAS is at a crucial inflection point. Can it deliver on its promise?

Kodiak Sciences launches a pivotal trial for a new drug aiming to best current treatments for diabetic eye disease. Is this the future of vision care?

As VolitionRx readies its Q2 update, investors and scientists look for proof that its pioneering epigenetic tests can translate into commercial success.

A novel dual-action antibody shows remarkable durability in Phase 2 trials, offering a potential six-month dosing schedule for millions with chronic sinusitis.

A new blood test for Alzheimer's from Spear Bio wins a top tech award. Its unprecedented sensitivity could revolutionize early detection and treatment.

Orchestra Life Sciences' meteoric rise on the Inc. 5000 is more than a growth story; it's a signal of the industrialization of advanced therapies.

With a strong cash position and key clinical trials advancing for ALS and FTD, Coya is executing a disciplined strategy to tackle neurodegenerative diseases.

The biotech has gone all-in on its lead drug, bel-sar, cutting 20% of staff and shelving a promising bladder cancer program to secure its financial future.

With promising data for its lead cancer drug and a fortified financial runway, C4 Therapeutics is executing a tangible plan to fight a relentless disease.

With 92% response rates in a deadly cancer and $1B in the bank, Tango Therapeutics is not just developing a drug—it's building a new industrial model for precision oncology.